Search research articles
Contact Us
Filters
Showing results (201-210 of 226) with videos related to
Page
of 23
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
February 9, 2026
Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials
John Nikitas, Parsa Jamshidian, Alison C Tree, et al.
The Lancet. Oncology
|
February 2, 2025
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials
John Nikitas, Parsa Jamshidian, Alison C Tree, et al.
The Journal of Clinical Investigation
|
June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Juliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
Clinical and Translational Radiation Oncology
|
December 1, 2022
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer
David J Thomson, Clare Cruickshank, Helen Baines, et al.
The Journal of Clinical Investigation
|
December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo, George Seed, Claudia Bertan, et al.
Cancer Discovery
|
September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Ebiomedicine
|
August 13, 2016
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer
Sarah L Kerns, Leila Dorling, Laura Fachal, et al.
Cancer Discovery
|
April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall, Joaquin Mateo, Wei Yuan, et al.
Trials
|
September 6, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
Sharon B Love, Fay Cafferty, Claire Snowdon, et al.
Cancer Cell
|
November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
George Seed, Nick Beije, Wei Yuan, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 226) with videos related to
Sort By:
Page
of 23
International Journal of Radiation Oncology, Biology, Physics
|
February 9, 2026
Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials
John Nikitas, Parsa Jamshidian, Alison C Tree, et al.
The Lancet. Oncology
|
February 2, 2025
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials
John Nikitas, Parsa Jamshidian, Alison C Tree, et al.
The Journal of Clinical Investigation
|
June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Juliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
Clinical and Translational Radiation Oncology
|
December 1, 2022
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer
David J Thomson, Clare Cruickshank, Helen Baines, et al.
The Journal of Clinical Investigation
|
December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo, George Seed, Claudia Bertan, et al.
Cancer Discovery
|
September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Ebiomedicine
|
August 13, 2016
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer
Sarah L Kerns, Leila Dorling, Laura Fachal, et al.
Cancer Discovery
|
April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall, Joaquin Mateo, Wei Yuan, et al.
Trials
|
September 6, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
Sharon B Love, Fay Cafferty, Claire Snowdon, et al.
Cancer Cell
|
November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
George Seed, Nick Beije, Wei Yuan, et al.
Page
of 23